In an adequately powered, randomized controlled trial conducted over 2 years, the desired clinical outcome (i.e. prevention of a serious cardiovascular event) with a new drug is achieved in 25% of the study sample. In the patients who receive a placebo, only 15% obtain the same clinical benefit. The relative risk reduction achieved with the new drug over the study period is:
Lauran
6 months agoPearly
6 months agoMargret
6 months agoKenneth
7 months agoBernardine
7 months agoFrederica
7 months agoGail
7 months agoTamra
7 months agoCary
8 months agoGerardo
8 months agoNatalie
8 months agoDevorah
8 months agoDorathy
8 months agoPhyliss
8 months agoTambra
1 year agoSamuel
11 months agoAudry
11 months agoOzell
11 months agoMarg
11 months agoAltha
1 year agoJamal
1 year agoPamella
11 months agoXenia
12 months agoSkye
12 months agoDeonna
12 months agoElvis
1 year agoDenise
12 months agoJaclyn
12 months agoTimothy
1 year agoYuonne
1 year agoMalcolm
12 months agoKizzy
1 year agoAndrew
1 year agoOmega
1 year agoThea
1 year agoMelynda
1 year agoEllen
1 year agoDaren
1 year agoRuth
1 year ago